GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Price-to-Free-Cash-Flow

Edgewise Therapeutics (Edgewise Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-01), Edgewise Therapeutics's share price is $19.005. Edgewise Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.53. Hence, Edgewise Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Edgewise Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

EWTX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.685
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Edgewise Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.42. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.53.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -68.80% per year.

During the past 5 years, Edgewise Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was -33.20% per year. The lowest was -68.80% per year. And the median was -51.00% per year.


Edgewise Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Edgewise Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Price-to-Free-Cash-Flow Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Edgewise Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Edgewise Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Edgewise Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edgewise Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's Price-to-Free-Cash-Flow falls into.



Edgewise Therapeutics Price-to-Free-Cash-Flow Calculation

Edgewise Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=19.005/-1.533
=N/A

Edgewise Therapeutics's Share Price of today is $19.005.
Edgewise Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.53.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Edgewise Therapeutics  (NAS:EWTX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Edgewise Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3415 Colorado Avenue, Boulder, CO, USA, 80303
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Executives
John R Moore officer: General Counsel 3200 WALNUT ST, BOULDER CO 80301
Alan J Russell director, officer: Chief Scientific Officer 3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan officer: Chief Business Officer 3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch director, officer: President and CEO 3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan officer: CMO C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran officer: Chief Development Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017